Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: Is it still viable?

Cancer Immunology, Immunotherapy

Volumn 58, Issue 9, 2009, Pages 1489-1499

  Riley, Catherine L ^a   Mathieu, Morgan G ^a   Clark, Richard E ^b   McArdle, Stephanie E B ^a   Rees, Robert C ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

BCR ABL; Cancer vaccine; CML; HAGE; Immunotherapy; Leukaemia

Indexed keywords

BCR ABL PROTEIN; CANCER VACCINE; DNA VACCINE; HAGE PROTEIN; HELICASE; HLA A2 ANTIGEN; HLA A3 ANTIGEN; HLA B7 ANTIGEN; IMATINIB; MYELOBLASTIN; PEPTIDE VACCINE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WT1 PROTEIN;

ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; DNA IMMUNIZATION; EPITOPE MAPPING; HLA TYPING; HUMAN; HUMAN CELL; IMMUNOGENICITY; LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM PROTEINS;

EID: 67649639394     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0675-x     Document Type: Review

References (58)

1. JK Adam B Odhav KD Bhoola 2003 Immune responses in cancer Pharmacol Ther 99 113 132 (Pubitemid 36700437)
2. SP Adams SS Sahota A Mijovic B Czepulkowski RA Padua GJ Mufti BA Guinn 2002 Frequent expression of HAGE in presentation chronic myeloid leukaemias Leukemia 16 2238 2242 (Pubitemid 35331839)
3. RJ Anderson J Schneider 2007 Plasmid DNA and Viral vector-based vaccines for the treatment of cancer Vaccine 25S B24 B34
4. F Baron R Storb 2006 The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective Best Pract Res Clin Haematol 19 637 653 (Pubitemid 44418027)
5. I Bellantuono L Gao S Parry S Marley F Dazzi J Apperley JM Goldman HJ Stauss 2002 Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL Blood 100 3835 3837 (Pubitemid 35303962)
6. M Bergant L Meden U Repnik V Sojar D Stanisavljević M Jeras 2006 Preparation of native and amplified tumour RNA for dendritic cell transfection and generation of in vitro anti-tumour CTL responses Immunobiology 211 179 189 (Pubitemid 43337758)
7. JS Bertram 2006 The molecular biology of cancer Mol Aspects Med 21 167 223
8. JA Berzofsky JD Ahlers IM Belyakov 2001 Strategies for designing and optimizing new generation vaccines Nat Rev Immunol 1 209 219 (Pubitemid 33741959)
9. M Bocchia S Gentili E Abruzzese A Fanelli F Iuliano A Tabilio M Amabile F Forconi A Gozzetti D Raspadori S Amadori F Lauria 2005 Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial Lancet 365 657 662 (Pubitemid 40260886)
10. KM Brauer D Werth K von Schwarzenberg A Bringmann L Kanz F Grünebach P Brossart 2007 BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells Cancer Res 67 5489 5497 (Pubitemid 46997290)
11. JM Burrows MJ Bell R Brennan JJ Miles R Khanna SR Burrows 2008 Preferential binding of unusually long peptides to MHC class I and its influence on the selection of target peptides for the T cell recognition Mol Immunol 45 1818 1824 (Pubitemid 351221138)
12. NM Butt JM Rojas L Wang SE Christmas HM Abu-Eisha RE Clark 2005 Circulating bcr-abl-specific CD8 + T cells in chronic myeloid leukemia patients and healthy subjects Haematologica 90 1315 1323 (Pubitemid 41503646)
13. K Cathcart J Pinilla-Ibarz T Korontsvit J Schwartz V Zakhaleva EB Papadopoulos DA Scheinberg 2004 A multivalent BCRABL fusion peptide vaccination trial in patients with chronic myeloid leukemia Blood 103 1037 1042 (Pubitemid 38129569)
14. E Celis A Sette HM Grey 1995 Epitope selection and development of peptide based vaccines to treat cancer Semin Cancer Biol 6 329 336
15. RE Clark IA Dodi SC Hill JR Lill G Aubert AR Macintyre J Rojas A Bourdon PL Bonner L Wang SE Christmas PJ Travers CS Creaser RC Rees JA Madrigal 2001 Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from BCR-ABL b3a2 fusion protein Blood 98 2887 2893
16. S Dermime A Armstrong RE Hawkins PL Stern 2002 Cancer vaccines and immunotherapy Br Med Bull 62 149 162 (Pubitemid 34832477)
17. S Dermime DE Gilham DM Shaw EJ Davidson el-K Meziane A Armstrong RE Hawkins PL Stern 2004 Vaccine and antibody-directed T cell tumour immunotherapy Biochim Biophys Acta 1704 11 35 (Pubitemid 38802995)
18. J Eberle LF Fecker JU Bittner CE Orfanos CC Geilen 2002 Decreased proliferation of human melanoma cell lines caused by antisense RNA against translation factor eIF-4A1 Br J Cancer 86 1957 1962 (Pubitemid 34888635)
19. M Gannagé M Abel AS Michallet S Delluc M Lambert S Giraudier R Kratzer G Niedermann L Saveanu F Guilhot L Camoin B Varet A Buzyn S Caillat-Zucman 2005 Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy J Immunol 174 8210 8218 (Pubitemid 40806333)
20. R Godbout M Packer W Bie 1998 Overexpression of a DEAD box protein (DDX1) in neuroblastoma and retinoblastoma cell lines J Biol Chem 273 21161 21168 (Pubitemid 28385405)
21. SM Graham HG Jørgensen E Allan C Pearson MJ Alcorn L Richmond TL Holyoake 2002 Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 99 319 325
22. G Grosveld A Hermans A De Klein D Bootsma N Heisterkamp J Groffen 1987 The role of the Philadelphia translocation in chronic myelocytic leukaemia Ann NY Acad Sci 511 262 269 (Pubitemid 18093049)
23. F Grünebach V Mirakaj V Mirakaj MR Müller T Brümmendorf P Brossart 2006 BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia Cancer Res 66 5892 5900 (Pubitemid 43927144)
24. HG Jørgensen EK Allan NE Jordanides JC Mountford TL Holyoake 2007 Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34 + CML cells Blood 109 4016 4019 (Pubitemid 46641755)
25. JH Kessler SA Bres-Vloemans PA van Veelen A de Ru IJ Huijbers M Camps A Mulder R Offringa JW Drijfhout OC Leeksma F Ossendorp CJ Melief 2006 BCR-ABL fusion regions as a source of multiple leukemia-specific CD8 + T-cell epitopes Leukemia 20 1738 1750 (Pubitemid 44574985)
26. A Kiani I Habermann K Schäke A Neubauer L Rogge G Ehninger 2003 Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukaemia not treated with interferon-alpha or imatinib Haematologica 88 754 761 (Pubitemid 36890109)
27. AJ Knights AO Weinzierl T Flad BA Guinn L Mueller GJ Mufti S Stevanovic G Pawelec 2006 A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias Leukemia 20 1067 1072 (Pubitemid 43797299)
28. JH Ma YF Sui J Ye YY Huang ZS Li GS Chen P Qu HP Song XM Zhang 2005 Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo Cancer Immunol Immunother 54 907 914 (Pubitemid 40991333)
29. S MacKinnon EB Papadopoulos MH Carabasi L Reich NH Collins F Boulad H Castro-Malaspina BH Childs AP Gillio NA Kernan 1995 Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease Blood 86 1261 1268
30. V Mailander C Scheibenbogen E Thiel A Letsch IW Blau U Keilholz 2004 Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity Leukemia 18 165 166 (Pubitemid 38159453)
31. PW Manley SW Cowan-Jacob J Mestan 2005 Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia Biochim Biophys Acta 1754 3 13 (Pubitemid 41797682)
32. AM Marmont MM Horowitz RP Gale K Sobocinski RC Ash DW van Bekkum RE Champlin KA Dicke JM Goldman RA Good 1991 T-cell depletion of HLA-identical transplants in leukemia Blood 78 2120 2130
33. V Martelange C De Smet E De Plaen C Lurquin T Boon 2000 Identification on a human sarcoma of two new genes with tumor-specific expression Cancer Res 60 3848 3855 (Pubitemid 32204577)
34. MG Mathieu AJ Knights G Pawelec CL Riley D Wernet FA Lemonnier PT Straten L Mueller RC Rees SE McArdle 2007 HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides Cancer Immunol Immunother 56 1885 1895 (Pubitemid 47512610)
35. N Meidenbaur TK Hoffmann AD Donnenberg 2003 Direct visualization of antigen-specific T cells using peptide-MHC class I tetrameric complexes Methods 31 160 171 (Pubitemid 37075901)
36. S Mocellin G Semenzato S Mandruzzato C Riccardo Rossi 2004 Part II: vaccines for haematological malignant disorders Lancet Oncol 5 727 737 (Pubitemid 39646782)
37. JS Moyer G Maine JJ Mulé 2006 Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects Biol Blood Marrow Transplant 12 1010 1019
38. M Nieda A Nicol A Kikuchi K Kashiwase K Taylor K Suzuki K Tadokoro T Juji 1998 Dendritic cells stimulate the expansion of bcr-abl specific CD8 + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia Blood 91 977 983 (Pubitemid 28078301)
39. E Orsini E Calabrese R Maggio A Pasquale M Nanni S Trasarti A Tafuri A Guarini R Foa 2006 Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation Leuk Res 30 785 794 (Pubitemid 43816701)
40. GJ Ossenkoppele AG Stam TM Westers TD de Gruijl JJ Janssen AA van de Loosdrecht RJ Scheper 2003 Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells Leukemia 17 1424 1426 (Pubitemid 36857358)
41. S Paczesny H Ueno J Fay J Banchereau AK Palucka 2003 Dendritic cells as vectors for immunotherapy of cancer Semin Cancer Biol 13 439 447 (Pubitemid 38156136)
42. RA Padua J Larghero M Robin C le Pogam MH Schlageter S Muszlak J Fric R West P Rousselot TH Phan L Mudde H Teisserenc AF Carpentier S Kogan L Degos M Pla JM Bishop F Stevenson D Charron C Chomienne 2003 PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia Nat Med 9 1413 1417 (Pubitemid 37466192)
43. JH Park CJ Kim JH Lee SH Shin GH Chung YS Jang 1999 Effective immunotherapy of cancer by DNA vaccination Mol Cells 9 384 391
44. J Pinilla-Ibarz K Cathcart DA Scheinberg 2000 CML vaccines as a paradigm of the specific immunotherapy of cancer Blood Rev 14 111 120 (Pubitemid 30616184)
45. M Rescigno F Avogadri G Curigliano 2007 Challenges and prospects of immunotherapy as cancer treatments Biochim Biophys Acta 1776 108 123 (Pubitemid 47332077)
46. JM Rojas K Knight L Wang RE Clark 2007 Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study Leukemia 21 2287 2295 (Pubitemid 350011701)
47. J Roman-Gomez A Jimenez-Velasco X Agirre JA Castillejo G Navarro E San Jose-Eneriz L Garate L Cordeu F Cervantes F Prosper A Heiniger A Torres 2007 Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia Haematologica 92 153 162
48. MJ Scanlan AJ Simpson LJ Old 2004 The cancer/testis genes: review, standardization, and commentary Cancer Immun 4 1
49. F Scheich J Duyster C Peschel H Bernhard 2007 The immunogenicity of Bcr-Abl-expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl-regulated antigens Blood 110 2556 2560 (Pubitemid 47523178)
50. S Siena M Di Nicola M Bregni R Mortarini A Anichini L Lombardi F Ravagnani G Parmiani AM Gianni 1995 Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy Exp Hematol 23 1463 1471 (Pubitemid 26035713)
51. T Takahashi Y Tanaka M Nieda T Azuma S Chiba T Juji Y Shibata H Hirai 2003 Dendritic cell vaccination for patients with chronic myelogenous leukemia Leuk Res 27 9 795 802 (Pubitemid 36683326)
52. KY Tsang S Zaremba CA Nieroda MZ Zhu JM Hamilton J Schlom 1995 Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine J Natl Cancer Inst 87 982 990
53. JB Ulmer B Wahren MA Liu 2006 Gene-based vaccines: recent technical and clinical advances Trends Mol Med 12 216 222 (Pubitemid 43728411)
54. DN Vatakis YT Koh M McMillan 2005 CD4 + T cell epitope affinity to MHC II influences the magnitude of CTL responses elicited by DNA epitope vaccines Vaccine 23 2639 2646 (Pubitemid 40380809)
55. K Watari A Tojo T Nagamura-Inoue F Nagamura A Takeshita T Fukushima T Motoji K Tani S Asano 2000 Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene FEBS Lett 466 367 371 (Pubitemid 30069860)
56. Q Yan YK Cheung SC Cheng XH Wang M Shi MH Hu X Yong 2007 A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses Gynecol Oncol 104 1 199 206 (Pubitemid 46070190)
57. L Yang C Lin ZR Liu 2005 Signaling to the DEAD box-regulation of DEAD-box p68 RNA helicase by protein phosphorylations Cell Signal 17 1495 1504 (Pubitemid 41253989)
58. Z Yu NP Restifo 2002 Cancer vaccines: progress reveals new complexities J Clin Invest 110 289 295